TipRanks
Advertisement
Advertisement

MX:1093N Stock Latest News

CSPC’s Efmedaglutide Shows Strong Phase III Results Against Dulaglutide in Chinese Diabetes Trial
Company AnnouncementsCSPC’s Efmedaglutide Shows Strong Phase III Results Against Dulaglutide in Chinese Diabetes Trial
3d ago
CSPC Wins U.S. FDA Nod for Clinical Trials of Recombinant Shingles Vaccine
PremiumCompany Announcements
CSPC Wins U.S. FDA Nod for Clinical Trials of Recombinant Shingles Vaccine
4d ago
CSPC Launches Phase Ib Trial of Obesity Biologic JMT206 in China
PremiumCompany Announcements
CSPC Launches Phase Ib Trial of Obesity Biologic JMT206 in China
4d ago
CSPC Wins China Trial Nod for Novel mRNA Cancer Vaccine SYS6077
PremiumCompany Announcements
CSPC Wins China Trial Nod for Novel mRNA Cancer Vaccine SYS6077
5d ago
CSPC’s Becotatug Combo Hits Key Goal in Phase III EGFR ex20ins Lung Cancer Trial
PremiumCompany Announcements
CSPC’s Becotatug Combo Hits Key Goal in Phase III EGFR ex20ins Lung Cancer Trial
9d ago
CSPC Launches Phase III Trial of Albumin-Bound Docetaxel for Advanced Breast Cancer in China
PremiumCompany AnnouncementsCSPC Launches Phase III Trial of Albumin-Bound Docetaxel for Advanced Breast Cancer in China
9d ago
CSPC Advances Novel Dual-Target Diabetes Drug Into Phase II Trial in China
Premium
Company Announcements
CSPC Advances Novel Dual-Target Diabetes Drug Into Phase II Trial in China
17d ago
CSPC’s ADC SYS6010 Wins Breakthrough Status in China for Hard-to-Treat Lung Cancer
Premium
Company Announcements
CSPC’s ADC SYS6010 Wins Breakthrough Status in China for Hard-to-Treat Lung Cancer
18d ago
CSPC Advances SYS6010 Lung Cancer Combo After Strong Phase I/II Data
PremiumCompany Announcements
CSPC Advances SYS6010 Lung Cancer Combo After Strong Phase I/II Data
19d ago
CSPC Wins China Trial Nod for First Ready-to-Use Goserelin Injection
PremiumCompany Announcements
CSPC Wins China Trial Nod for First Ready-to-Use Goserelin Injection
24d ago
CSPC Wins NMPA Nod for First Subcutaneous Long-Acting Rotigotine Parkinson’s Trial in China
PremiumCompany Announcements
CSPC Wins NMPA Nod for First Subcutaneous Long-Acting Rotigotine Parkinson’s Trial in China
24d ago
CSPC Wins China Trial Approval for Innovative SYH2083 Eye Drops
PremiumCompany Announcements
CSPC Wins China Trial Approval for Innovative SYH2083 Eye Drops
25d ago
CSPC Launches Phase II Trial of Novel Influenza Drug in China
PremiumCompany AnnouncementsCSPC Launches Phase II Trial of Novel Influenza Drug in China
26d ago
CSPC’s SYS6010 Wins Third Breakthrough Therapy Tag in High-Need Cancer Indications
Premium
Company Announcements
CSPC’s SYS6010 Wins Third Breakthrough Therapy Tag in High-Need Cancer Indications
1M ago
CSPC Launches Phase I Trial of Novel Depression Drug SYH2056 in China
Premium
Company Announcements
CSPC Launches Phase I Trial of Novel Depression Drug SYH2056 in China
1M ago
CSPC Launches First China Trial for New Obesity Drug SYH2092
PremiumCompany Announcements
CSPC Launches First China Trial for New Obesity Drug SYH2092
1M ago
CSPC Advances Dual-Agonist Obesity Drug SYH2069 Into Phase II Trial in China
PremiumCompany Announcements
CSPC Advances Dual-Agonist Obesity Drug SYH2069 Into Phase II Trial in China
1M ago
CSPC Wins China Trial Approval for Novel Obesity and Diabetes Drug
PremiumCompany Announcements
CSPC Wins China Trial Approval for Novel Obesity and Diabetes Drug
1M ago
CSPC Cancer Drug SYS6090 Wins U.S. FDA Fast Track Status
PremiumCompany Announcements
CSPC Cancer Drug SYS6090 Wins U.S. FDA Fast Track Status
1M ago
CSPC’s EGFR-Targeting ADC Hits Phase III Milestone in Resistant Lung Cancer
PremiumCompany AnnouncementsCSPC’s EGFR-Targeting ADC Hits Phase III Milestone in Resistant Lung Cancer
1M ago
CSPC Wins U.S. and China Approvals to Trial New RSV Vaccine in Seniors
Premium
Company Announcements
CSPC Wins U.S. and China Approvals to Trial New RSV Vaccine in Seniors
1M ago
CSPC Pharmaceutical: Buy Rating Reaffirmed as Earnings Visibility Improves and DCF-Based Target Price Raised to HK$13.44
Premium
Ratings
CSPC Pharmaceutical: Buy Rating Reaffirmed as Earnings Visibility Improves and DCF-Based Target Price Raised to HK$13.44
1M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >